Alpha 2.0
Login Register
» Authors » Andrea R Menicucci

Andrea R Menicucci

Explore the profile of Andrea R Menicucci including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 239
Followers 0
Related Specialties
Oncology
Science
Allergy & Immunology
Top 10 Co-Authors
Ilhem Messaoudi
William Audeh
Allen Jankeel
Lisa E Blumencranz
Thomas W Geisbert
Courtney Woolsey
Erin B Yoder
Robert W Cross
Andrea Marzi
Christine Finn
Published In
Sci Rep
Front Immunol
JCO Precis Oncol
Ann Surg Oncol
J Virol
Affiliations
Soon will be listed here.
Recent Articles
1.
Clinicopathologic and molecular characterization of low-grade, early-stage, and HER2-positive invasive breast carcinoma
Hunter N, Han L, Corbin H, Konnick E, Gwin 3rd W, Vinayak S, et al.
Am J Clin Pathol . 2025 Mar; PMID: 40043195
Objectives: Breast carcinomas overexpressing human epidermal growth factor receptor 2 (HER2) are typically associated with higher tumor grade and faster progression. HER2 positivity is rare in low-grade breast carcinomas with...
2.
Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial
J van t Veer L, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, van de Velde C, Kleijn M, Dreezen C, et al.
JAMA Netw Open . 2024 Nov; 7(11):e2447530. PMID: 39602119
Importance: There is a need for biomarkers that predict late recurrence risk and extended endocrine therapy (EET) benefit among patients with early-stage breast cancer (EBC). MammaPrint, a 70-gene expression risk-of-recurrence...
3.
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial
Rastogi P, Bandos H, Lucas P, J van t Veer L, Wei J, Geyer Jr C, et al.
J Clin Oncol . 2024 Jul; 42(30):3561-3569. PMID: 39047219
Purpose: MammaPrint (MP) determines distant metastatic risk and may improve patient selection for extended endocrine therapy (EET). This study examined MP in predicting extended letrozole therapy (ELT) benefit in patients...
4.
Prediction of Benefit From Adjuvant Pertuzumab by 80-Gene Signature in the APHINITY (BIG 4-11) Trial
Krop I, Mittempergher L, Paulson J, Andre F, Bonnefoi H, Loi S, et al.
JCO Precis Oncol . 2024 Jan; 8:e2200667. PMID: 38237097
Purpose: At the primary analysis, the APHINITY trial reported a statistically significant but modest benefit of adding pertuzumab to standard adjuvant chemotherapy plus trastuzumab in patients with histologically confirmed human...
5.
The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
Blumencranz P, Habibi M, Shivers S, Acs G, Blumencranz L, Yoder E, et al.
Ann Surg Oncol . 2023 Sep; 30(13):8353-8361. PMID: 37658272
Background: Neoadjuvant chemotherapy (NCT) increases the feasibility of surgical resection by downstaging large primary breast tumors and nodal involvement, which may result in surgical de-escalation and improved outcomes. This subanalysis...
6.
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer
Pellicane J, Beitsch P, Rock D, Budway R, Dul C, Kelemen P, et al.
Surg Oncol . 2022 Nov; 45:101885. PMID: 36436423
Background: As more patients with early-stage breast cancer receive neoadjuvant endocrine therapy (NET), there is a need for reliable biomarkers that can identify patients with HR+ HER2- tumors who are...
7.
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy
Whitworth P, Beitsch P, Murray M, Richards P, Mislowsky A, Dul C, et al.
JCO Precis Oncol . 2022 Sep; 6:e2200197. PMID: 36108259
Purpose: The prospective Neoadjuvant Breast Registry Symphony Trial compared the 80-gene molecular subtyping signature with clinical assessment by immunohistochemistry and/or fluorescence in situ hybridization in predicting pathologic complete response (pCR)...
8.
BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance
Kuilman M, Ellappalayam A, Barcaru A, Haan J, Bhaskaran R, Wehkamp D, et al.
Breast Cancer Res Treat . 2022 Aug; 195(3):263-274. PMID: 35984580
Purpose: BluePrint (BP) is an 80-gene molecular subtyping test that classifies early-stage breast cancer (EBC) into Basal, Luminal, and HER2 subtypes. In most cases, breast tumors have one dominant subtype,...
9.
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature
Whitworth P, Beitsch P, Pellicane J, Baron P, Lee L, Dul C, et al.
JCO Precis Oncol . 2022 Apr; 6:e2100463. PMID: 35476550
Purpose: The 80-gene molecular subtyping signature (80-GS) reclassifies a proportion of immunohistochemistry (IHC)-defined luminal breast cancers (estrogen receptor-positive [ER+], human epidermal growth factor receptor 2-negative [HER2-]) as Basal-Type. We report...
10.
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer
Whitworth P, Beitsch P, Pellicane J, Baron P, Lee L, Dul C, et al.
Ann Surg Oncol . 2022 Apr; PMID: 35378634
Background: The Neoadjuvant Breast Symphony Trial (NBRST) demonstrated the 70-gene risk of distant recurrence signature, MammaPrint, and the 80-gene molecular subtyping signature, BluePrint, precisely determined preoperative pathological complete response (pCR)...